Using modified stem cell particles to treat degenerative disc disease
Extracellular vesicles produced by CRISPR-activated MSCs: A potential therapy for degenerative disc disease
This study is exploring a new treatment for low back pain caused by degenerative disc disease, using tiny particles from specially modified stem cells to help reduce inflammation and promote healing in your discs, which could lead to less pain and better movement.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rochester Institute of Technology NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10873279 on NIH RePORTER |
What this research studies
This research investigates the use of extracellular vesicles (EVs) produced by genetically modified mesenchymal stem cells (MSCs) as a potential therapy for degenerative disc disease (DDD), a common cause of low back pain. The approach focuses on enhancing the regenerative properties of these EVs to combat inflammation and promote healing in the intervertebral discs. By modifying MSCs to increase the production of specific proteins, the study aims to improve the therapeutic effects of the EVs without the complications associated with direct cell therapies. Patients may benefit from a novel treatment option that could alleviate pain and improve mobility.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing chronic low back pain due to degenerative disc disease.
Not a fit: Patients with acute back pain not related to degenerative disc disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, less invasive treatment option for patients suffering from degenerative disc disease.
How similar studies have performed: While the use of extracellular vesicles in therapy is a relatively novel approach, preliminary studies have shown promise in similar applications.
Where this research is happening
Rochester, United States
- Rochester Institute of Technology — Rochester, United States (Active)
Researchers
- Principal investigator: Wuertz-Kozak, Karin — Rochester Institute of Technology
- Study coordinator: Wuertz-Kozak, Karin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.